Kenvue Inc. (KVUE) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

65/ 100

GoAI Score

Buy

Valuation

84

Deep Value

Sentiment

54

Mixed

Risk

23

Moderate Risk

Momentum

49

Neutral

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Industry: Household & Personal Products
Sector: Consumer Defensive
Headquarters: US
CEO: Kirk L. Perry
Listed since: May 4, 2023
Employees: 21,890

Market position

Day range

Current $17.74

$17.485$17.745

52-week range

Current $17.74

$14.02$20.13

Open: $17.66
Previous close: $17.70
Volume: 14.15M; 0.65× average
Average volume: 21.8M; Average daily volume
Market cap: 34.06B USD
Beta: 0.45; Market reference 1
50-day average: $18.4464; -3.83% below average
200-day average: $18.0457; -1.69% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 40.42B USD
P/E (TTM): 20.39×
P/B (TTM): 3.23×
P/S (TTM): 2.21×
EV / EBITDA: 13.77×
Earnings yield: 4.46%
Free cash flow yield: 5.23%
Dividend yield: 5.88%

Profitability & efficiency

Gross margin: 58.19%
Operating margin: 19.52%
Net margin: 10.76%
Return on equity: 13.66%
Return on assets: 5.43%
Return on invested capital: 8.80%

Financial health

Debt / equity: 0.8×
Current ratio: 0.96×
Altman Z-score: 2.15
Piotroski F-score: 5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

15.12B USD-2.14%

Operating income

2.7B USD+46.88%

Net income

1.47B USD+42.72%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	15.12B USD	15.46B USD	15.44B USD	14.95B USD	15.05B USD
Cost of goods sold	6.33B USD	6.5B USD	6.8B USD	6.67B USD	6.64B USD
Gross profit	8.79B USD	8.96B USD	8.64B USD	8.29B USD	8.42B USD
Research and development	382M USD	—	—	—	—
Selling, general, and administrative	6.09B USD	6.03B USD	6.14B USD	5.63B USD	5.48B USD
Operating expenses	6.09B USD	7.12B USD	6.13B USD	5.61B USD	5.5B USD
Interest income	—	53M USD	108M USD	—	—
Interest expense	379M USD	431M USD	358M USD	—	—
Depreciation and amortization	557M USD	622M USD	627M USD	644M USD	731M USD
Operating income	2.7B USD	1.84B USD	2.51B USD	2.68B USD	2.92B USD
Net income	1.47B USD	1.03B USD	1.66B USD	2.06B USD	2.08B USD

Company facts updated Oct 12, 2026.

Earnings

EPS beat rate: 82%; 9 beats, 1 miss, 1 met estimate
Average EPS surprise: +8.66%; 11 comparable reports
Latest EPS result: 0.31; Estimate 0.32 · Miss by 2.73%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Latest fiscal-year EPS: 0.76; FY2025 · +40.74% year over year
Latest fiscal-year revenue: 15.12B USD; FY2025 · -2.14% year over year
Next fiscal-year EPS consensus: 1.18; FY2026 · 8 analysts
Next fiscal-year revenue consensus: 15.6B USD; FY2026 · 10 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$19.50

9.92% upside

Past 12 months12-month forecastHigh $20.00Average $19.50Low $19.00

Rating distribution

14 ratings

Strong buy00%

Buy429%

Hold1071%

Sell00%

Strong sell00%

Recent analyst actions

12 institutions

KVUE news

247wallst.comOct 8, 2026

Market Concentration Is Spooking Wall Street—I'm Buying Kenvue

While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and the reasoning…

Read source

zacks.comOct 6, 2026

NWL or KVUE: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Newell Brands (NWL) or Kenvue (KVUE). But which of these two stocks is more attractive to value investors?

Read source

247wallst.comOct 4, 2026

4 Dividend Aristocrats Still Raising Their Payouts No Matter What Their Stock Price Did

One of these stocks lost nearly a fifth of its value over the past year, another nearly doubled, and both still handed shareholders a bigger check. Find out whether the dividends behind these very different charts are…

Read source

prnewswire.comOct 1, 2026

Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team

Russ Torres to Depart Kimberly-Clark for External CEO Role Carlos De Jesus to be Appointed as President, North America and Leonardo Curado to be Appointed as President, EMEA After Kenvue Acquisition DALLAS, Oct. 1, 2026…

Read source

247wallst.comSep 30, 2026

5 ‘Bulletproof’ Dividend Kings Boomers Should Buy Now Before the Market Shifts

Rising rates have boomers flocking to Treasuries, but five battle-tested dividend payers with 50-plus years of consecutive increases may offer something bonds simply cannot deliver.

Read source

247wallst.comSep 29, 2026

Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?

Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%.

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.825

2025 complete year+1.9% since 2024

2026 partial: $0.835

$0.81

2,024

$0.825

2,025

$0.835

2,026*

* Partial calendar year in the available dividend history.

Corporate action history

Action	Ex-dividend date	Details	Record date	Payment date
Dividend	Sep 21, 2026	$0.21Monthly	Sep 21, 2026	Oct 2, 2026
Dividend	Aug 12, 2026	$0.21Quarterly	Aug 12, 2026	Aug 26, 2026
Dividend	May 13, 2026	$0.2075Quarterly	May 13, 2026	May 27, 2026
Dividend	Feb 11, 2026	$0.2075Quarterly	Feb 11, 2026	Feb 25, 2026
Dividend	Nov 12, 2025	$0.2075Quarterly	Nov 12, 2025	Nov 26, 2025
Dividend	Aug 13, 2025	$0.2075Quarterly	Aug 13, 2025	Aug 27, 2025